Compare AdaptHealth Corp (AHCO) vs Freeport-McMoRan Inc (FCX) Price & Performance

AdaptHealth (AHCO) trades at $5.77, up 2.12% today, but faces a bearish technical trend with recent earnings misses and a net loss of $70.79 million in 2025. Revenue grew to $3.24 billion, yet profitability remains challenged with a negative net margin. The company is refocusing on sleep and respiratory care after selling its diabetes unit, but faces multiple securities fraud investigations following a significant Q2 2026 earnings shortfall.

The outlook is cautious; while analyst consensus is bullish with a $11.00 price target, near-term risks from legal probes, execution missteps, and margin pressure outweigh potential upside. Investor sentiment is negative due to guidance cuts and operational challenges, making the stock high-risk despite its low valuation multiples.

FCX trades at $66.83, down 2.98% on the day, but maintains a bullish technical trend with strong analyst support. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 expected at $0.72 EPS. Revenue remains stable around $25.9B, while net income margin improved to 11.38% in 2026. Recent news highlights operational challenges like lower copper volumes but also growth initiatives at Grasberg and Bagdad.

The outlook is positive with a consensus price target of $73.85, implying ~10% upside. Key opportunities include exposure to high copper prices and expansion projects, while risks involve production volatility, cost pressures, and reliance on commodity cycles. The stock's valuation appears elevated with a P/E of 33.93, requiring sustained earnings growth to justify further gains.